News
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
3 Top Small-Cap Stocks to Buy in December
Small-cap stocks are riskier than their blue-chip peers, but they can also deliver incredible gains. The trick is finding solid businesses that the rest of the market is overlooking, putting your....
Alnylam Gets Some Welcome News
The FDA has agreed to allow Alnylam (NASDAQ: ALNY) and Sanofi (NYSE: SNY) to resume trials of their hemophilia therapy, fitusiran. Previously, these companies had to halt their fitusiran studies....
This Tiny Biotech Pins Hope on U.S. Approval
Amicus Therapeutics (NASDAQ: FOLD) already markets its Fabry disease drug Galafold overseas, and it hopes it will soon be able to help patients in the U.S., too. Yesterday, management reported....
What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm....
ASH 2017 Recap: These Were the Big Winners and Losers
The American Society of Hematology's (ASH) conference is one of biopharma's biggest annual events. This year's meeting was packed with market-moving presentations, but perhaps the biggest....
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
Wall Street finally gave up some ground on Thursday, as the Dow Jones Industrials finished down more than 75 points. Major benchmarks generally posted modest losses of half a percent or less as....
Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a....
Why Genomic Health, Inc. Skyrocketed Today
Genomic Health (NASDAQ: GHDX) is up 21% at 1:12 p.m. EST Thursday after Bloomberg reported that the cancer test company is contemplating selling itself after receiving takeover interest.While it's....
Why Teva Pharmaceutical Is Soaring 13.5% Today
After providing investors with the details of its latest cost-savings plan, including a massive workforce reduction, Teva Pharmaceutical (NYSE: TEVA) shares are rallying 13.5% as of 1 p.m. EST....
Here's Why Marinus Pharmaceuticals Is Soaring Today
Welcome to the popular clique, kid. Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose as much as 22.2% by noon EST after the company announced it will be added to the....
BOIRON : Acquisition of trademarks and patents
The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes....
BOIRON : Acquisition de marques et brevets
Les Laboratoires BOIRON ont acquis auprès de la société suisse ALKANTIS les marques et brevets relatifs à son dispositif médical à visée antalgique, anti-inflammatoire et anti-œdémateuse....
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Why ImmunoGen, Inc. Jumped Higher Today
Shares of ImmunoGen (NASDAQ: IMGN) closed up 12% as the American Society of Hematology (ASH) meeting wraps up. The biotech presented over the weekend, which shouldn't be affecting the price of....
Here's Why Everyone's So Excited About bluebird bio
Investors have seen bluebird bio's (NASDAQ: BLUE) share price skyrocket following impressive early-stage trial results for bb2121, a multiple myeloma gene therapy that's licensed to Celgene Corp.....
5 Biotech Buyout Candidates for 2018
With the Republican tax plan steaming through both houses of Congress, 2018 is shaping up to be a banner year in terms of consolidation for the biotechnology industry. Biopharmaceutical....
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....
AbbVie Makes Progress on Quest to Diversify
AbbVie's (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide....
This Is Why Global Blood Therapeutics Inc. Is Sinking Today
In response to the company announcing data from a case study at the American Society of Hematology meeting in Atlanta, shares of Global Blood Therapeutics (NASDAQ: GBT), a clinical-stage biotech....
3 Reasons Spark Therapeutics Is a Buy After Its Crash
After Spark Therapeutics and competitor BioMarin Therapeutic (NASDAQ: BMRN) updated investors on the progress that they're making developing competing gene therapies for hemophilia, investors....
Here's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November
Shares of Inovio Pharmaceuticals Inc. (NASDAQ: INO), a biopharmaceutical company developing vaccines, fell 21.3% in November according to data from S&P Global Market Intelligence. Despite....
QUANTUM GENOMICS : Symposium Quantum Genomics sur les inhibiteurs de l'aminopeptidase A cérébrale à l'occasion des 37èmes Journées de l'hypertension artérielle à Paris
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), société biopharmaceutique spécialisée dans le développement d'une nouvelle classe de médicaments agissant directement sur le cerveau....
Here's Why GlycoMimetics Is Soaring 24.3% Higher Today
After unveiling updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML), GlycoMimetics (NASDAQ: GLYC) shares are surging 24.3% as of noon EST....